EP1743650A3 - Interféron félin contre dermatite atopique féline - Google Patents

Interféron félin contre dermatite atopique féline Download PDF

Info

Publication number
EP1743650A3
EP1743650A3 EP06018590A EP06018590A EP1743650A3 EP 1743650 A3 EP1743650 A3 EP 1743650A3 EP 06018590 A EP06018590 A EP 06018590A EP 06018590 A EP06018590 A EP 06018590A EP 1743650 A3 EP1743650 A3 EP 1743650A3
Authority
EP
European Patent Office
Prior art keywords
feline
atopic dermatitis
intrerferon
interferon
feline interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06018590A
Other languages
German (de)
English (en)
Other versions
EP1743650A2 (fr
EP1743650B1 (fr
Inventor
Tsunesuke Kajimoto
Makoto Suzuki
Ryougai Go
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of EP1743650A2 publication Critical patent/EP1743650A2/fr
Publication of EP1743650A3 publication Critical patent/EP1743650A3/fr
Application granted granted Critical
Publication of EP1743650B1 publication Critical patent/EP1743650B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP06018590A 1996-10-31 1997-10-30 Interféron félin contre dermatite atopique féline Expired - Lifetime EP1743650B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29060196A JP3845915B2 (ja) 1996-10-31 1996-10-31 ネコのアトピー性皮膚炎治療剤および治療方法
EP97909701A EP0875251B1 (fr) 1996-10-31 1997-10-30 Agent therapeutique diriges contre les infection par le fiv

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP97909701A Division EP0875251B1 (fr) 1996-10-31 1997-10-30 Agent therapeutique diriges contre les infection par le fiv

Publications (3)

Publication Number Publication Date
EP1743650A2 EP1743650A2 (fr) 2007-01-17
EP1743650A3 true EP1743650A3 (fr) 2007-03-21
EP1743650B1 EP1743650B1 (fr) 2009-03-25

Family

ID=17758124

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97909701A Expired - Lifetime EP0875251B1 (fr) 1996-10-31 1997-10-30 Agent therapeutique diriges contre les infection par le fiv
EP06018590A Expired - Lifetime EP1743650B1 (fr) 1996-10-31 1997-10-30 Interféron félin contre dermatite atopique féline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97909701A Expired - Lifetime EP0875251B1 (fr) 1996-10-31 1997-10-30 Agent therapeutique diriges contre les infection par le fiv

Country Status (8)

Country Link
US (1) US6194381B1 (fr)
EP (2) EP0875251B1 (fr)
JP (1) JP3845915B2 (fr)
CA (2) CA2241941C (fr)
DE (2) DE69739332D1 (fr)
ES (2) ES2323326T3 (fr)
PT (2) PT875251E (fr)
WO (1) WO1998018484A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40374E1 (en) 1998-05-29 2008-06-10 Heska Corporation Canine IL-13 immunoregulatory proteins and uses thereof
US20020127200A1 (en) 1998-05-29 2002-09-12 Shumin Yang Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
US6482403B1 (en) * 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
AU4102099A (en) 1998-05-29 1999-12-13 Heska Corporation Canine Interleukin -4 Proteins, Nucleic Acid Molecules, and Uses Thereof
WO2002036627A2 (fr) * 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, utilisations et compositions associees

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414355A1 (fr) * 1989-06-29 1991-02-27 Toray Industries, Inc. Interféron félin et procédé de production par un vecteur viral du ver à soie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853523T2 (de) * 1987-12-29 1995-08-17 Toray Industries Synthetisches Plasmid, transformierte Zelle, Katzen-Interferon-Gen und Verfahren zur Herstellung von Katzen-Interferon.
JP2982177B2 (ja) * 1989-06-14 1999-11-22 東レ株式会社 発現プラスミド、形質転換酵母および該酵母を用いたネコインターフェロンの製造法
JP3640980B2 (ja) * 1993-04-09 2005-04-20 株式会社林原生物化学研究所 ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法
JP3269125B2 (ja) * 1994-01-28 2002-03-25 東レ株式会社 アトピー性皮膚炎治療薬
GB9414752D0 (en) * 1994-07-21 1994-09-07 Q One Biotech Ltd Feline gamma-interferon
JPH0940580A (ja) * 1995-07-28 1997-02-10 Boehringer Ingelheim Internatl Gmbh 抗ＨＩＶ剤ＩＦＮ−ω

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414355A1 (fr) * 1989-06-29 1991-02-27 Toray Industries, Inc. Interféron félin et procédé de production par un vecteur viral du ver à soie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADOLF G R ET AL: "PURIFICATION AND CHARACTERIZATION OF NATURAL HUMAN INTERFERON OMEGA 1 TWO ALTERNATIVE CLEAVAGE SITES FOR THE SIGNAL PEPTIDASE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 265, no. 16, 1990, pages 9290 - 9295, XP002929489, ISSN: 0021-9258 *
DOLEN JALE G ET AL: "Undetectable interferon-alpha serum levels in a patient with atopic dermatitis", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 15, no. 11, 1995, pages 973 - 975, XP009076981, ISSN: 1079-9907 *
HALPERN MICHAEL ET AL: "Regulation of the low affinity IgE Fc receptor (CD23) in atopic dermatitis", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 100, no. 3, 1993, pages 197 - 200, XP009076980, ISSN: 1018-2438 *
HELTON-RHODES, K.: "Feline Immunomodulators - Current Veterinary Therapy XII", 1995, BONAGURA, J.D., PHILADELPHIA, XP009076995 *
SCOTT D W ET AL: "Medical management of allergic pruritus in the cat, with emphasis on feline atopy.", JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION. JUN 1993, vol. 64, no. 2, June 1993 (1993-06-01), pages 103 - 108, XP009076899, ISSN: 1019-9128 *

Also Published As

Publication number Publication date
DE69737088D1 (de) 2007-01-25
ES2275283T3 (es) 2007-06-01
CA2241941A1 (fr) 1998-05-07
EP1743650A2 (fr) 2007-01-17
ES2323326T3 (es) 2009-07-13
CA2241941C (fr) 2008-11-18
JPH10130165A (ja) 1998-05-19
DE69737088T2 (de) 2007-04-12
EP0875251A1 (fr) 1998-11-04
WO1998018484A1 (fr) 1998-05-07
EP1743650B1 (fr) 2009-03-25
PT1743650E (pt) 2009-06-25
US6194381B1 (en) 2001-02-27
CA2638985C (fr) 2011-11-29
DE69739332D1 (de) 2009-05-07
EP0875251B1 (fr) 2006-12-13
JP3845915B2 (ja) 2006-11-15
EP0875251A4 (fr) 2004-04-21
PT875251E (pt) 2007-01-31
CA2638985A1 (fr) 1998-05-07

Similar Documents

Publication Publication Date Title
AU6338196A (en) Rectification, derectification and power flow control
AU1214495A (en) Bipolar battery construction
AU2480397A (en) Gain controller
AU2440997A (en) Calixpyrroles, calixpyridinopyrroles and calixpyridines
GB9610159D0 (en) Low cost, high reliability soft start arrangement
AU1808595A (en) 3,8-diazabicyclo{3.2.1}octane derivatives having analgesic activity
AU2911995A (en) Electrochemical light-emitting devices
EP0690039A3 (fr) Alcools et acides substitués avec des groupes poly-perfluoroalkyles, et leurs dérivés
AU6878894A (en) 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
AU2957997A (en) 1,2,4-oxadiazoles as adhesion-receptor antagonists
AU2584497A (en) Determinant spar assembly
AU1981095A (en) Seat elevating device
AU1559897A (en) Bumper, and the fabrication thereof
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
AU4565197A (en) Colostrinin, and uses thereof
AU5855498A (en) Monoolefinic c5-mononitriles, method for the production and the use thereof
AU1483295A (en) Benzimidazoles
AU3053495A (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide derivatives
AU4330796A (en) Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz(b,f)oxepines
AU7697394A (en) 4-alkylamino-1-phenoxyalkyl piperidines as antiinflammatory, antiallergic and immunomodulating agents
AU623728B2 (en) Valve, and set point pressure controller utilizing the same
AU1441195A (en) Phenylmethyl hexanamides, and the use thereof
AU4511489A (en) 14alpha,17alpha-ethano-estratrienes
AU3853097A (en) Benzimidazole derivatives, preparation thereof, and therapeutical uses thereof
AU2885595A (en) Telephone connection method, particularly for conference calls and the like

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060905

AC Divisional application: reference to earlier application

Ref document number: 0875251

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE DE ES FR GB IT NL PT

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KAJIMOTO, TSUNESUKE

Inventor name: SUZUKI, MAKOTO

Inventor name: GO, RYOUGAI

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE DE ES FR GB IT NL PT

17Q First examination report despatched

Effective date: 20070510

AKX Designation fees paid

Designated state(s): BE DE ES FR GB IT NL PT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0875251

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE DE ES FR GB IT NL PT

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69739332

Country of ref document: DE

Date of ref document: 20090507

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090617

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2323326

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091229

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20160913

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20160919

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20160913

Year of fee payment: 20

Ref country code: BE

Payment date: 20160913

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20161026

Year of fee payment: 20

Ref country code: DE

Payment date: 20161025

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20161024

Year of fee payment: 20

Ref country code: PT

Payment date: 20161027

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69739332

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20171029

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20171029

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20171030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20171108

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20171029

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20171031